Join the club for FREE to access the whole archive and other member benefits.


University of Exeter spinout developing senotherapeutic interventions through modulation of dysregulated RNA splicing

SENISCA is a biotech spinout company from the University of Exeter, founded in 2020 and dedicated to the development of new approaches to reverse cellular senescence (senotherapeutics).

Our founders are world leaders in molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence. This innovation works by restoring the ability of cells to ‘fine tune’ the expression of their genes to rejuvenate aged cells.

At SENISCA, we are using this knowledge, concerning how and why cells become senescent, to develop a new generation of interventions, to turn back the ageing clock in old cells and to target the diseases and aesthetic signs of ageing. SENISCA interventions are small molecule or oligonucleotide-based.

Senisca Executive Team

  • Sarah Cole, CEO
  • Lorna Harries - CSO
  • Ben Lee - CTO
  • Kirsty Semple - COO
  • Tim Schmidt - CDO

Senisca Advisory Board

  • David Chiswell - Chairman
  • Allan Weiner - Non-Executive Director
  • Scott Beattie - Non-Executive Director
  • Richard Haycock - Non-Executive Director
  • Steve Wilton - Scientific Advisor

Visit website:



See also: Academia University of Exeter - UK university and member of the Russell Group of leading research-intensive UK universities

Details last updated 05-Aug-2020

Mentioned in this Resource

Allan Weiner

Non Executive Director at SENISCA

Ben Lee

Chief Technical Officer at SENISCA

David Chiswell

Chairman at Senisca

Kirsty Semple

Chief Executive Officer and Co-founder of SENISCA

Lorna Harries

Professor of Molecular Genetics at the University of Exeter

Richard Haycock

Co-founder and CEO of QantX, Non-Executive Director at SENISCA

Sarah Cole

Chief Executive Officer at Senisca

Scott Beattie

Non-Executive Director at Senisca

Steve Wilton

Foundation Chair in Molecular Therapies at Murdoch University

Tim Schmidt

Chief Development Officer at SENISCA


Reason reports back from Rejuvenation Startup Summit 2024

Fight Aging! - 13-May-2024

A great summary of 25 speakers who are in various stages of platform building, drug discovery and clinical trials


SENISCA secures 3.7 million euros to fight aging with RNA-based therapies

Longevity Technology - 18-Mar-2024

Developing senotherapeutics to target cellular senescence and treat age-related diseases


Reason reports back from Age-Related Disease Therapeutics Summit 2023

Fight Aging! - 16-Jun-2023

Many people believe lots of clinical trials of novel therapeutics targeting mechanisms of aging will start up in the next few years


Exeter's company SENISCA raises £2 million to treat age-related chronic diseases

University of Exeter - 09-Jun-2022

Funding might allow RNA-based rejuvenation tech to enter ex vivo lab tests


SENISCA to reverse senescence by targeting RNA splicing patterns

Longevity Technology - 08-Apr-2022

Lorna Harries details significant breakthroughs at fourth annual Longevity Leaders World Congress


SENISCA targets sensescence using a new ageing hallmark - dysregulated mRNA processing (LEAF) - 03-Nov-2021

Lorna Harries believes dysregulated splicing as a breakthrough senotherapeutic target


SENISCA secures 1.3 million pounds to transform anti-ageing technology

University of Exeter - 12-Mar-2021

Spin out company from University of Exeter step forward towards precision medicine for age-related diseases


LMC provides background and success outlook on 14 leading senolytic companies

Longevity Marketcap - 15-Dec-2020

Comprehensive review of companies' clinical and financial state of play


Nature Biotechnology reviews the state of play of senolytics

Nature Biotechnology - 12-Nov-2020

In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...


Taking the new path in the field of senolytics - SENISCA

Longevity Technology - 29-Jul-2020

Old cells will be more young and beautiful

Topics mentioned on this page:
Senescent Cells